Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
S. Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
R. Vij
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene
Honoraria - Bristol-Myers Squibb; Celgene
T. Facon
Consultant or Advisory Role - Bristol-Myers Squibb
P. Moreau
No relevant relationships to disclose
X. Leleu
No relevant relationships to disclose
A. Mazumder
No relevant relationships to disclose
J. L. Kaufman
Consultant or Advisory Role - Keryx; Millennium; Onyx
Research Funding - Celgene; Merck
C. Westland
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
C. Tsao
Employment or Leadership Position - Abbott Biotherapeutics
A. K. Singhal
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
S. Jagannath
Consultant or Advisory Role - Celgene; Merck; Millennium